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Background: Neuroinflammation often results in enduring cognitive impairment and is a risk factor for postoperative
cognitive dysfunction. There are currently no effective treatments for infection-induced cognitive impairment. Previous
studies have shown that the iron chelator deferoxamine (DFO) can increase the resistance of neurons to injury and
disease by stimulating adaptive cellular stress responses. However, the impact of DFO on the cognitive sequelae of
neuroinflammation is unknown.
Methods: A mouse model of lipopolysaccharide (LPS)-induced cognitive impairment was established to evaluate the
neuroprotective effects of DFO against LPS-induced memory deficits and neuroinflammation. Adult C57BL/6 mice were
treated with 0.5 μg of DFO 3 days prior to intracerebroventricular microinjection of 2 μg of LPS. Cognitive function was
assessed using a Morris water maze from post-injection days 1 to 3. Animal behavioral tests, as well as pathological and
biochemical assays were performed to evaluate the LPS-induced hippocampal damage and the neuroprotective effect
of DFO.
Results: Treatment of mice with LPS resulted in deficits in cognitive performance in the Morris water maze without
changing locomotor activity, which were ameliorated by pretreatment with DFO. DFO prevented LPS-induced
microglial activation and elevations of IL-1β and TNF-α levels in the hippocampus. Moreover, DFO attenuated elevated
expression of caspase-3, modulated GSK3β activity, and prevented LPS-induced increases of MDA and SOD levels in the
hippocampus. DFO also significantly blocked LPS-induced iron accumulation and altered expression of proteins related
to iron metabolism in the hippocampus.
Conclusions: Our results suggest that DFO may possess a neuroprotective effect against LPS-induced neuroinflammation
and cognitive deficits via mechanisms involving maintenance of less brain iron, prevention of neuroinflammation, and
alleviation of oxidative stress and apoptosis.
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Neuroinflammation has been reported as a part of the neu-
ropathogenesis of cognitive impairment [1]. The elderly are
vulnerable to the adverse effects of infections on cognitive
function, and the aging process itself is associated with en-
hanced neuroinflammatory processes involving microglial
activation and production of pro-inflammatory cytokines
[2,3]. Neuroinflammation also occurs in association with* Correspondence: mwd1962@sina.cn
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unless otherwise stated.the pathological changes in the brain of patients who have
undergone an operation and patients with Alzheimer’s dis-
ease (AD) or ischemic stroke [4,5]. However, the exact
mechanism underlying the effect of neuroinflammation on
cognitive function has not been completely clarified yet.
Lipopolysaccharide (LPS) is a major bacterial TLR4 lig-
and that activates the innate immune response to infec-
tions, and administration of LPS by systemic injection [6],
intracerebral microinjection, or chronic infusion [7-9] can
cause cognitive impairment in animal models. Previous
studies have shown that LPS can result in cognitive im-
pairment through mechanisms involving expression ofThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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tosis [10-14]. It is known that pro-inflammatory mediators
disrupt hippocampal neuronal functions, including long-
term potentiation and working memory consolidation
[15,16]. Cytokines such as TNF-α and IL-1β are involved
in hippocampal long-term potentiation and dendritic
branching, which are processes involved in memory for-
mation and maintenance [17]. Activation of microglia by
LPS has been linked to the pathogenesis of neuronal
death, neurogenesis failure, and hippocampus-dependent
memory and synaptic plasticity impairments; however, the
mechanisms responsible for these effects are not well
understood [18], although brain tissue oxidative damage
has been considered an important contributor to memory
impairment induced by LPS [19].
Evidence also suggests that aberrant iron accumulation
in the brain plays a pivotal role in the pathogenesis of
many diseases involving cognitive dysfunction [20-22].
The major mechanism of iron-mismanagement was re-
lated to increased iron uptake by DMT1, Tf/TfR2, and
Lf/LfR [23-25], decreased iron export by FPN and Cp
[26,27], and iron storage misregulation by ferritin and ly-
sosomes [28-30]. In fact, it has been demonstrated that
iron overload can lead to free radical formation, oxidative
stress, and neuronal damage [20,31-34]. Neuroinflamma-
tion has been found in many iron-associated neurodegen-
erative diseases such as AD, Parkinson’s disease (PD), and
demyelinating diseases such as multiple sclerosis and
amyotrophic later sclerosis [35-39].
Based on the above findings, we hypothesized that de-
creasing iron content in the brain during neuroinflamma-
tion might decrease microglial activation and inflammatory
cytokines in the hippocampus, and thus improve cognitive
impairment. To test this hypothesis, we assessed the neu-
roprotective effects of iron chelator deferoxamine (DFO)
against LPS-induced neuroinflammation in the present
study. In order to remove any potential confounding ef-
fects of the peripheral immune system, the present set
of experiments were carried out by challenging mice by
intracerebroventricular injection of LPS. The results ob-
tained in this study may provide new insights into the




Male C57BL/6 mice aged 10 to 12 weeks, weighing 20
to 22 g, were obtained from the Beijing SPF Animal
Technology Company (Beijing, China). The animals were
housed in a temperature- and humidity-controlled room
with a 12-h light/dark cycle starting at least 5 days be-
fore the experiment and had access to water and food
ad libitum. They were group-housed with the same
mates throughout the acclimation and testing periods.Animal experiments were performed in compliance with
the current laws of China and the National Institutes of
Health Guide for the Care and Use of Laboratory Animals
(NIH publication No. 86–23, revised 1996).
Establishment of a mouse model of LPS-induced cognitive
impairment
To optimize the dose of LPS for inducing cognitive im-
pairment, mice were randomly assigned into five groups
(n = 8 for each) and administered with 0, 0.01, 0.1, 2,
and 5 μg of LPS (in 2 μL of artificial cerebrospinal fluid
(aCSF); Sigma, St. Louis, MO, USA) by stereotactic in-
tracerebroventricular injection 5 days after acquisition
training in a Morris water maze (MWM). The aCSF ve-
hicle contained 140 mM NaCl, 3.0 mM KCl, 2.5 mM
CaCl2, 1.0 mM MgCl2, and 1.2 mM Na2HPO4, adjusted
to pH 7.4. The probe test for reference memory was
conducted 1 day after LPS administration, and working
memory was tested on days 1 to 3 after LPS administra-
tion to observe whether the impairment could recover
spontaneously and the duration it needed.
Optimization of dose of DFO to alter LPS-induced
cognitive impairment
Six randomly assigned groups of mice were intracerebro-
ventricularly administrated with 0, 0, 0.1, 0.5, 2.5, and 5 μg
of DFO (in 2 μL of aCSF; Sigma) 3 days prior to micro-
injection of LPS. All groups received intracerebroventricu-
lar administration of LPS (2 μg in 2 μL of aCSF), except
the first group that received equal volume of aCSF and
served as a control group. Mice were allowed to rest for
6 h before MWM acquisition training on the day of DFO
administration and the probe test for reference memory
was conducted 1 day after LPS administration.
Effect of DFO on LPS-induced cognitive impairment
in mice
One hundred mice were randomly assigned into four
groups: control, DFO, LPS, and LPS + DFO (n = 25 for
each). Intracerebroventricular administration of DFO
(0.5 μg in 2 μL of aCSF) was commenced 3 days prior to
microinjection of LPS (2 μg in 2 μL of aCSF), while the
control group received equal volume of aCSF.
For stereotactic injection of LPS and DFO, mice were
anesthetized with Avertin (200 mg/kg, intraperitoneal in-
jection) and placed on a stereotactic apparatus (Kopf
Instruments, Tujunga, CA, USA). Injection was performed
through drilled holes in the skull, into the paracele using
the following coordinate (in mm): 0.5 posterior, ± 1.0
lateral and 2.0 ventral from bregma. The injection speed
was set at 0.667 μL/min and the needle was left in place
for 1 min following injection.
Body weights were determined daily. The mice were
sacrificed by CO2 asphyxiation 6, 24, 48, or 72 h following
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with ice-cold PBS. The brain of five mice killed at 24 h in
each group were immediately removed, fixed in 4% para-
formaldehyde for 48 h and cryoprotected in 30% sucrose
for 48 h at 4°C, followed by histological analysis. The
hippocampus of the other mice were rapidly dissected out
and stored at −80°C until analysis. Tissues of mice killed
at 6 h were used for enzyme-linked immunosorbent assay
(ELISA) for measuring inflammatory cytokines because it
is known that LPS activates microglia and consequently
induces pro-inflammatory protein secretion within 6 h in
the mouse hippocampus via the NF-κB pathway [40,41].
All other tests were carried out on postinjection day 1 that
corresponded to the time point of the peak of behavioral
deficits.
Open field test
To evaluate whether the reversion of lesioned perform-
ance by LPS depends on altering the locomotor activity,
we assessed the numbers of line crossings and rears in
mice [42]. Mice were placed in the corner of a plastic
box (36 × 29 × 23 cm) in which the base was divided into
equal sectors for a 5-min acclimation period, and then
the numbers of crossings (with all four paws placed into
a new square) and rears (with both front paws raised
from the floor) were recorded over the next 5 min. The
open field was cleaned with 5% ethyl alcohol and
allowed to dry between tests.
MWM test
The MWM test, which is a hippocampal-dependent test
of spatial learning and memory for rodents, was per-
formed as described previously with minor modifications
[43]. In this test mice rely on distal cues to navigate from
start locations around the perimeter of an open swim-
ming arena (diameter, 122 cm; water temperature, 22°C)
to locate a submerged escape platform (10 cm2). Spatial
learning is assessed across repeated trials for 5 days
(day −5 to day −1). The pool was situated in a room with
visual cues. The animals’ movements were recorded
with a video camera attached to the ceiling. Mice were
released into the water facing the wall of the pool from
one of four separate quadrants. In all the trials, mice
were allowed to swim until they landed on the plat-
form. If a mouse failed to find the platform within 60 s,
it was picked up and placed on the platform for 10 s.
After that, the mouse was removed to its cage and the
second animal was tested on Trial 1. This rotation was
repeated until all animals completed Trial 1. Subse-
quently, the process was repeated for subsequent trials
until four trials completed per day for 5 consecutive days.
After the daily session, each mouse was dried under a heater
and returned to the home cage. On the third day of acquisi-
tion training (day −3), microinjection of DFO (or ACSF)was executed 6 h before training. On day 0, animals
underwent LPS microinjection. On postoperative day 1,
mice were subjected to the probe test for reference
memory during which the platform was absent. Swim-
ming speed, platform-site crossings, distance around
the platform, and the percentage of distance travelled
in the target quadrant were recorded. Each mouse was
placed in the pool once for 60 s, starting from the op-
posite quadrant to the platform. Reference memory was
determined by preference for the platform area. On
days 1, 2 and 3, working memory was tested, during
which both the platform and mice were randomly placed
in a novel position to assess working- or trial-dependent
learning and memory. In this procedure, which is also
called matching-to-sample, the animal is given two trials
per day. On each day, the first trial represents a sample
trial. During the sample trial, the animal must learn the
new location of the platform by trial and error. Trial 2 is
the test or matching trial in which savings in recall be-
tween Trial 1 and Trial 2 are measured. Trial 2 begins
after a 15-s inter-trial interval. If the animal recalls the
sample trial, it will swim a shorter path to the goal on
the second trial. As the platform is moved daily, no
learning of platform position from the previous day can
be transferred to the next day’s problem; hence, recall
on each day during Trial 2 is dependent on that day’s
sample trial and measures only temporary or working
memory, during which the latency to the novel platform
was recorded.
Immunofluorescence staining
Coronal sections (12 μm) were cut through the entire
hippocampus using a Microm HM550 cryostat (Germany).
Immunofluorescence staining was performed as previously
described by Jennifer et al. [44]. Briefly, sections were in-
cubated in 0.05% H2O2 in 0.1 M PBS for 20 min to block
endogenous peroxidase, and in 2% goat serum/0.1% Tri-
ton X-100 in 0.1 M PBS for 1 h to block non-specific bind-
ing sites. The sections were then incubated with the
primary antibody (rabbit anti-Iba1, 1:500; Wako) to label
microglia at 4°C overnight. Following that, the sections
were incubated with the appropriate secondary antibody
(anti-rabbit IgG, 1:200; Jackson, USA) for 2 h at room
temperature. Glial reactivity is characterized by an in-
crease in the number of cells and an alteration in cell
morphology (rounding of the cell bodies and thickening of
processes), which lead to an increase in labeling with
increasing glial reactivity. An increase in the integrated
intensity/pixel area for Iba1 (ionized calcium-binding
adaptor molecule 1) staining was interpreted to signify
microglial reactivity. The number of Iba1-labeled cells per
view was counted using fluorescence microscopy at × 20
magnification and the mean density at × 100 magnifica-
tion. Images were captured using the Leica TCS SP5
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Plus 6.0 software.
ELISA
Concentrations of IL-1β and TNF-α were examined by
ELISA using IL-1β and TNF-α ELISA assay kits (R&D
Systems, USA). Hippocampal tissues were homogenized
in RIPA lysis buffer (Applygen, China). Supernatant pro-
tein concentrations were determined after centrifugation
at 12,000 g for 15 min with a BCA protein assay kit
(Pierce, USA). For each sample, 10 μg of extracted pro-
tein was used for detection. The procedure followed the
manufacturer’s instructions. The absorbance was read
on a spectrophotometer at a wavelength of 450 nm and
a reference wavelength of 650 nm. The concentrations
of IL-1β and TNF-α were calculated according to the
standard curve and presented as pg/μg protein.
Western blot analysis
Western blot was performed following the manufacturer’s
instructions. Equal amounts (50 μg) of proteins were sepa-
rated by SDS-PAGE and analyzed by western blot using
the following primary antibodies: anti-caspase-3 (1:500;
Proteintech), anti-pGSK-3β (Ser9) (1:1,000; Cell Signaling),
anti-GSK-3β pan (1:1,000; Cell Signaling), anti-ferritin (Fn;
1:500; Abcam), and anti-ferroportin 1(FPN; 1:1,000; Life-
span). The expression of a housekeeping protein, β-actin,
was measured using an anti-β-actin antibody (1:500; Santa
Cruz). Each experiment was repeated at least four times.
Relative expression levels of proteins were normalized to
β-actin.
Iron content determination
Total iron content in the hippocampus was determined
using a flame atomic absorption spectrophotometer
(VarianAA240FS, USA). Hippocampal tissues were
weighed, dried at 65°C for 24 h and then digested at
100°C with nitric acid and 30% hydrogen peroxide [45].
Digested samples were well mixed and further diluted.
A blank sample was included as a baseline reference for
every run. Accuracy was checked using an internally
prepared solution. The standard addition method was
used for calibration. Standard and control samples were
prepared in an identical manner to the experimental
samples.
MDA concentration and SOD activity assays
Level of malondialdehyde (MDA), a well-established in-
dicator of lipid peroxidation, and the activity of super-
oxide dismutase (SOD), an endogenous scavenger of
reactive oxygen species (ROS), in the hippocampal tissue
were measured using commercial assay kits (Nanjing
Jiancheng, China) according to the manufacturer’s in-
structions. The results of MDA and SOD are expressedas nanomoles of MDA per milligram of total protein
(nmol/mg protein) and units per milligram of total pro-
tein (U/mg protein), respectively.
Statistical analysis
All data were analyzed by an observer who was blind to
the experimental protocol. Intergroup comparisons were
conducted by two-way analysis of variance (2 × 2
ANOVA), followed by a Dunnett post hoc test where ne-
cessary. For acquisition training (days −1 to −5) and
spatial working memory testing (days 1 to 3), data were
analyzed using two-way ANOVA (treatment × trial time)
with repeated measures (trial days) followed by the
Bonferroni post hoc test. For all other data, two-way
ANOVA was used. All results are expressed as mean ±
standard error (SE), and P values <0.05 were considered
statistically significant.
Results
Deferoxamine prevents memory deficits caused by
experimental cerebral inflammation
To elucidate the effect of LPS and DFO on hippocampal-
dependent learning and memory, an MWM test was
conducted. In the preliminary experiment designed for de-
termining the optimal dose of LPS, intracerebroventricular
administration of 2 μg of LPS (in 2 μL of aCSF) induced
memory impairment but no swimming speed change in
the MWM. Mice in the LPS group performed worse on
day 1 (P = 0.0449 for crossings and P = 0.0406 for distance
around the platform in reference memory test; P =0.0162
for latency in working memory test; n = 8; Figure 1A-C)
following microinjection after 5 days of acquisition train-
ing, but the performance returned to control levels on day
3, which suggested that LPS induced a temporary impair-
ment in spatial learning and memory (P = 0.2232 for la-
tency in working memory test; n = 8; Figure 1C).
On above basis, the experiment for determining the
optimal dose of DFO showed that intracerebroventricu-
lar administration of 0.5 μg of DFO (in 2 μL of aCSF)
3 days before LPS microinjection could ameliorate the
memory deficits (P = 0.0122 for crossings; P = 0.0215 for
distance around the platform; n = 8; Figure 1D, E).
To elucidate the effect of LPS and DFO on hippocampal-
dependent learning and memory, an MWM test was con-
ducted [43]. Mice initially received 5 days of acquisition
training with the platform in a fixed location. On day 6, ani-
mals underwent microinjection surgery, and on postopera-
tive day 1, mice were subjected to a probe test for reference
memory, during which the platform was absent, as well as
an open field test for locomotion activity. On days 1 to 3,
mice were subjected to a working memory test, during
which both the platform and mice were randomly placed in
a novel position to assess working- or trial-dependent
learning and memory. If the animal recalls the sample trial,
Figure 1 Preliminary experiments to test the optimal doses of LPS to induce cognitive dysfunction and DFO to attenuate it by the
Morris water maze test. Intracerebroventricular LPS reduced platform crossings (A) and distance around the plat (B) in reference memory
test 1 day following microinjection after 5 days of training, and latency to plat (C) in working memory on post-injection days 1 to 3, 2 μg LPS
in particular. DFO attenuated LPS-induced reduction of crossings (D) and distance around the platform (E), with 0.5 μg of DFO being more
significant. Data are expressed as mean ± SE (n = 8). *P <0.05 vs. control; #P <0.05 vs. LPS. Con, control; DFO, deferoxamine; LPS, lipopolysaccharide;
SE, standard error.
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Two-way ANOVA revealed that during the acquisition
phase, the performance of all groups improved over time,
and no differences were observed between groups (data not
shown). During the probe test, there were no significant
differences in swimming speed between groups, suggesting
that the poorer performance of the LPS group was not a re-
sult of reduced motor ability (Figure 2A). It was observed
that deferoxamine prevented memory deficits caused
by LPS on postoperative day 1 (FLPS = 2.441, FDFO = 0.8651,
FLPS×DFO = 4.186 for platform-site crossings, P <0.05;
FLPS = 2.192, FDFO = 2.693, FLPS×DFO = 3.070 for percentage
of distance travelled in the target quadrant during probe
testing, P <0.05; Figure 2B, C). Similar results were ob-
served in latency to the platform during the working mem-
ory test and performance returned to control levels on day
3 (FLPS = 2.924 and 3.078, FDFO = 3.652 and 0.6747,
FLPS×DFO = 1.417 and 0.4951 for days 1 and 2, respectively,
P <0.05; Figure 2D).
To evaluate whether the lesioned performance caused
by LPS depends on altering the locomotor activity, the
open field test was conducted [46]. No significant differ-
ence was observed in the locomotor performance (line
crossings and rears) 24 h after LPS treatment (LPS andDFO + LPS groups) when compared with the control
and DFO groups (Figure 2E, F).
To confirm that central LPS induced a sickness re-
sponse, we measured the change in body weight [47,48].
As expected, mice intracerebroventricularly injected
with 2 μg of LPS lost body weight over a 3-day period
following treatment (FLPS = 290.9, 95.34, and 9.024 for
days 1, 2, and 3, respectively, P <0.05; Figure 2G). How-
ever, that loss was significantly reduced by pretreatment
with DFO (FDFO = 2.427, 1.974, and 0.7966 for days 1, 2,
and 3, respectively, P <0.05; Figure 2G).
Collectively, our results suggest that LPS causes cognitive
impairment, specifically a deficit in short-term memory re-
tention, which can be ameliorated by DFO pretreatment.
DFO suppresses LPS-induced accumulation of inflammatory
proteins in the hippocampus
In view of the important role that cytokines and micro-
glial activation play in LPS-induced neuroinflammation
[8,11,49,50], we investigated the levels of several pro-
inflammatory cytokines and proteins (IL-1β, TNF-α,
Iba1) in the hippocampus, a brain region where neuroin-
flammation mainly occurs in response to brain injury
and inflammation [51,52]. Immunohistochemistry and
Figure 2 DFO ameliorates behavioral performance in LPS-exposed mice. The Morris water maze test was performed as described in the
Methods section. (A) Swimming speed during probe testing. (B) Platform-site crossings during probe testing. (C) Percentage of distance travelled
in the target quadrant during probe testing. (D) Latency to the platform during spatial working memory testing on days 1, 2, and 3. (E, F) Results
of spontaneous locomotor activity showing that neither LPS nor DFO altered the number of line crossings (E) or rears (F) 24 h after LPS administration.
(G) Changes of body weight on days 1, 2, and 3. Data are expressed as mean ± SE (n= 25). *P <0.05, **P <0.01, ***P <0.001 vs. control; #P <0.05, ##P <0.01
vs. LPS. Con, control; DFO, deferoxamine; LPS, lipopolysaccharide; SE, standard error.
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microglial activation labeled by Iba1 (FLPS =105.3,
P <0.001 and FLPS’ = 46.27, P <0.01 for number and
density, respectively; Figure 3C, D) and significant in-
creases in IL-1β (t = 0.0005 control vs. LPS 6 h, n = 6;
Figure 3E) and TNF-α levels (t = 0.0006 control vs. LPS
6 h, n = 6; Figure 3F) in the hippocampus. Remarkably,
DFO significantly attenuated LPS-induced microglial
activation (FDFO = 5.208, P <0.01 and FDFO’ = 3.549, P <0.01
for number and density, respectively; Figure 3C, D) in
the hippocampus of mice, as well as increases in IL-1β(t = 0.0388 LPS 6 h vs. DFO + LPS 6 h, n = 6; Figure 3E)
and TNF-α (t = 0.0.0411 LPS 6 h vs. DFO + LPS 6 h,
n = 6; Figure 3F) levels.
DFO pretreatment prevents caspase-3 increase and blocks
glycogen synthase kinase 3β (GSK3β) activity in mice with
LPS-induced hippocampal impairment
To investigate cell death following intracerebroventricu-
lar administration of LPS with or without pretreatment
of DFO, apoptotic marker caspase-3 was evaluated [53].
Western blot analysis showed that LPS induced caspase-
Figure 3 Deferoxamine (DFO) attenuates lipopolysaccharide (LPS)-induced microglial activation and inflammatory cytokine accumulation.
(A, B) Representative images of Iba1-labeled activated microglia in the hippocampal C1 area. Activated microglia is shown in green. Scale bars = 40 μm
for (A) and 10 μm for (B). (C, D) Quantification of the Iba+ cell average number and the mean grey intensity. (E, F) Levels of IL-1β and TNF-α in samples
of the hippocampus. Data are expressed as mean ± SE (n = 6). *P <0.05, ***P <0.001 vs. control; #P <0.05 vs. LPS. Con, control; DFO, deferoxamine; LPS,
lipopolysaccharide; SE, standard error.
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caspase-3 activation (FLPS = 50.93, P <0.001; FDFO =
20.77, P <0.001; Figure 4D), suggesting that DFO may al-
leviate LPS-induced apoptosis in the hippocampus.
Given the critical roles of GSK3β in apoptosis and cog-
nitive function, we extended our experiments to deter-
mine whether DFO is able to modulate GSK3β activity in
the LPS-exposed mouse hippocampus [54,55]. The total
expression level of GSK3β was not changed by different
treatments (FLPS = 5.67, P >0.05; FDFO = 2.56, P >0.05;
Figure 4E), whereas the phospho-GSK3β/GSK3β ratio in
the hippocampus of LPS-lesioned mice was significantly
decreased, and DFO attenuated this reduction (FLPS =
23.36, P <0.001; FDFO = 6.663, P <0.05; Figure 4F). These
data suggest that DFO treatment downregulates GSK3β
activity by phosphorylating GSK3β in the hippocampus. In
the LPS-treated hippocampus, total GSK3β remained un-
changed and the activation of GSK3β was relatively in-
creased compared with the vehicle control. Collectively,
our data revealed that LPS and DFO antagonistically exerttheir effects on caspase-3 accumulation and p-GSK3β/
GSK3β pathways in the mouse hippocampus.
DFO reverses altered iron content and expression of Fn
and FPN proteins in the hippocampus of LPS-exposed
mice
To determine the changes in iron content and metabol-
ism, we investigated the effect of LPS or DFO on iron
content and the expression levels of proteins involved in
the maintenance of brain iron homeostasis by flame
atomic absorption spectrophotometery and western blot,
respectively [20,45]. A significant increase in iron con-
tent was observed on postoperative day 1 following LPS
microinjection in the LPS group, and the biggest in-
crease was 66.16% as compared with the control group
(FLPS = 9.588, P <0.01; n = 8; Figure 5A). Nevertheless,
DFO dramatically blocked this increase (FDFO = 18.61,
P <0.001; n= 8; Figure 5A). Fn is a ubiquitous and highly con-
served iron-binding protein, and it is a major form of non-
heme iron store in cells. The levels of Fn immunoreactivity
Figure 4 Effect of DFO on the expression of caspase-3 and p-GSK3β/GSK3β proteins in mice with LPS-induced hippocampal impairment.
(A-C) Protein bands on gel and their relative intensities. (D-F) The expression levels of caspase-3 and p-GSK3β/GSK3β proteins were normalized to that
of β-actin as an internal control. Data are expressed as mean ± SE (n = 4–5). *P <0.05, ***P <0.001 vs. control; #P <0.05, ###P <0.001 vs. LPS. Con, control;
DFO, deferoxamine; LPS, lipopolysaccharide; SE, standard error.
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tive day 1, and consistent with the hypothesis that DFO is
a high-affinity iron chelator to bind Fe3+, especially Fn and
heme iron, DFO reversed accumulation of Fn in the
hippocampus of LPS-exposed mice (FLPS = 13.42, P <0.05;
FDFO = 7.695, P <0.01; n = 5; Figure 5C). On the contrary,Figure 5 Effect of DFO on iron content and expression of Fn and FPN
(A) Iron content in the hippocampus is indicated as μg per gram tissue (n
The expression levels of Fn and FPN proteins were normalized to that of β
SE. *P <0.05, **P <0.01, ***P <0.001 vs. control; #P <0.05, ###P <0.001 vs. LP
standard error.FPN, an iron exporter which is present extensively on the
neurons, oligodendrocytes and astrocytes and plays an
important and probably even only role in iron efflux
from these cells, decreased in the LPS group, and the de-
crease was weakened by DFO pretreatment (FLPS = 99.48,
P <0.001; FDFO = 60.82, P <0.001; n = 4; Figure 5D).proteins in mice with LPS-induced hippocampal impairment.
= 8). (B) Protein bands on gel and their relative intensities. (C, D)
-actin as an internal control in (n = 4–5). Data are expressed as mean ±
S. Con, control; DFO, deferoxamine; LPS, lipopolysaccharide; SE,
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level and decrease of SOD activity
Given that increased levels of iron can lead to oxidative
stress, which in turn is detrimental to neuronal function
[56,57], we assessed whether LPS was also linked to an
increase in oxidative stress and whether improvement of
poor behavior and above impairment was related to a
decrease in oxidative stress in the hippocampus. We
measured the level of MDA, which is a byproduct of
lipid peroxidation and indicator of oxidative stress, and
the activity of SOD, which is one of the major antioxi-
dant enzymes involved in protecting the nervous tissue
from oxidative stress. Our data indicated that MDA level
was about twice that of the control and that SOD activ-
ity was reduced in the hippocampus of mice in the LPS
group on postoperative day 1 (FLPS = 22.05, P <0.001,
n = 9 for MDA; FLPS = 90.59, P <0.001, n = 12 for SOD;
Table 1). However, the status of less iron, which DFO
treatment resulted in, considerably weakened this lesion
(FDFO = 0.8509, P <0.05, n = 9 for MDA; FDFO = 0.2774,
P <0.05, n = 12 for SOD; Table 1). Meanwhile, no signifi-
cant difference was found between the DFO-alone and
control groups.
Discussion
A wide array of health benefits of DFO have been re-
ported in different animal models and human studies
[58-60]. In contrast, no studies evaluating the effect of
DFO in neuroinflammatory processes induced by LPS
administration have been conducted to date. Based on
previous studies showing that DFO can protect neurons
against degeneration in animal models of brain injury
that involves local inflammatory processes, PD and AD
[54,61,62], and evidence that sepsis can cause cognitive
impairment in human subjects [63,64], we hypothesized
that DFO might modify the adverse effects of regional
inflammation on cognitive function. Using LPS to elicit
an immune response, we observed a significant impair-
ment of memory performance in the MWM test, which
was counteracted by DFO.
The MWM was chosen as a robust and reliable test
that is strongly correlated with hippocampal-dependent
memory [65-67]. As we have stated, both spatial refer-
ence memory and working memory were tested [43].Table 1 MDA concentration (nmol/mg protein) and SOD
activity (U/mg protein).
Con DFO LPS DFO + LPS
SOD 109.2 ± 4.971 98.11 ± 10.55 51.05 ± 6.99a 67.03 ± 5.18b
MDA 0.1752 ± 0.0366 0.216 ± 0.0303 0.362 ± 0.0124a 0.3346 ± 0.0115b
Data are expressed as mean ± SE.
aP <0.001 vs. control.
bP <0.05 vs. LPS.
Con, control; DFO, deferoxamine; LPS, lipopolysaccharide; SE, standard error.Trial-dependent learning was assessed using a modified
protocol. Search-to-platform area determines the degree
of reliance on spatial vs. non-spatial strategies. Cued tri-
als determine whether performance factors that are un-
related to place learning are present. Escape from water
is relatively immune from activity or body mass differ-
ences, making it ideal for experimental models. In the
preliminary experiment we chose 10 ng, 100 ng, 2 μg,
and 5 μg of LPS (intracerebroventricular administration)
because these dosages have been reported to induce
sickness behavior in mice [68-71], and we sought
whether they could impair cognitive function and which
one is the applicable and preferred option. We observed
no significant differences between groups during the ac-
quisition phase, and 2 μg of LPS (intracerebroventricular
administration) caused memory deficits on postoperative
day 1 following the microinjection. Mice treated with
2 μg of LPS did not remember where the platform was,
and searched aimlessly instead. Both 10 ng and 100 ng
may not be sufficient to induce a cognitive decline, but
the reason that 5 μg failed to impact behavioral perform-
ance remains unknown. We speculate that it triggered
some self-protective mechanisms, but this speculation
needs future verification. Similarly, we chose 0.5, 1, 2.5,
and 5 μg of DFO for blocking LPS-induced behavioral
lesions because they were defined to be protective for in-
flammatory attack, so did the 3 days of time span for
pretreatment [71]. We found that 0.5 μg of DFO amelio-
rated the memory deficits caused by LPS. Likely, we
believe that 0.1 μg of DFO was not able to withstand
LPS-induced inflammatory cascade, but 2.5 and 5 μg of
DFO removed overmuch iron from neurons, hindering
iron-indispensable activities like the tricarboxylic acid
cycle and thus playing a harmful role [72-74].
In formal experiments, similar results were obtained
using 2 μg of LPS and 0.5 μg of DFO. Despite no differ-
ence in locomotor activity, DFO prevents memory deficits
caused by cerebral administration of inflammatory bacter-
ial LPS both in cue- and trial-dependent learning, which
mirrors spatial conference and working memory [43]. In
terms of body weight loss, intracerebroventricular LPS in-
duced a sickness response for over 3 days. In the present
study, intracerebroventricular LPS induced sickness be-
havior, as measured by body weight loss and decreased
spatial memory. However, these impairments were signifi-
cantly attenuated by pretreatment with DFO, a high-
affinity iron chelator to bind Fe3+ [75]. Collectively, our
results indicate that LPS causes cognitive impairment, spe-
cifically a deficit in short-term memory retention, which
can be ameliorated by DFO pretreatment. This finding
suggests a potential application of DFO to patients with or
at risk for cognitive impairment.
Cognitive decline is prominent in patients who undergo
various operations, and also occurs in other disorders in
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role [76]. Thus, we next evaluated the effect of DFO on
neuroinflammatory processes induced by LPS administra-
tion. Microglia is the resident macrophage in the brain,
participates in the coordination of events important for
the maintenance of neuronal health, and plays the most
important role in responding to inflammation in the cen-
tral nervous system. Previous studies [8,40,41] have shown
that LPS activates microglia and consequently induces
pro-inflammatory protein secretion within 6 h via the
NF-κB pathway in the mouse hippocampus. Release of
these pro-inflammatory cytokines by microglia fuels a
cycle of neuroinflammation that can cause bystander dam-
age to neurons [77]. In the current study, we demon-
strated that intracerebroventricular injection of LPS
induced increases in TNF-α and IL-1β levels in the mouse
brain 6 h after the injection and at 24 h postinjection, they
returned to the baseline levels. In addition, microglia la-
beled by Iba1 in the hippocampus was activated. Our re-
sults showed that DFO inhibited LPS-induced microglial
activation and production of pro-inflammatory mediators
including TNF-α and IL-1β. Since that increased iron
levels could affect the functional properties of activated
microglia at the secretory and gene expression levels
and that DFO possesses protective properties against
LPS-induced increased iron levels and neural injury, we
infer that these effects of DFO are associated with de-
creased activation of inflammatory cascades linked to pro-
inflammatory response [62,71,78].
As reported previously, LPS causes cognitive lesions
and this process involves apoptosis [79,80]. Thus, we in-
vestigated whether cell death induced by treatment with
intracerebroventricular LPS occurred via apoptosis and
whether iron was involved. To address this question,
caspase-3 activation, an apoptotic marker, was evaluated
[81,82]. Caspase-3 as an important executer of apoptosis,
was observed to elevate in the LPS-exposed hippocam-
pus and this increase was prevented by DFO pretreat-
ment, from which we could infer that DFO, or the
opposite factor iron, may intervene in LPS-induced cell
death. On the other hand, GSK3 as a downstream target
of Akt regulates many crucial cellular processes in the
brain and acts as an important positive regulator of the
inflammatory process [83,84]. GSK-3β overexpression
induces apoptosis and causes a drastic decrease in post-
synaptic density number and volume in hippocampal
granule neurons [85], a phenomenon that may be related
to cognitive impairment. In this study we observed that
intracerebroventricular LPS depressed the phospho-
GSK3β/GSK3β ratio in the hippocampus, and dysregula-
tion of this signal transduction pathway could result in
failure to adequately repress GSK-3β, thus allowing
GSK-3β to remain abnormally active. Such a status is
proved to contribute to various pathologies, includingneurodegenerative and cognitive disorders, which is in
line with the behavioral performance [81,83]. However,
DFO alleviated the reduction by phosphorylating GSK3β
in the hippocampus and regulated GSK-3β activity in
response to LPS, thus providing protection from LPS-
induced apoptosis and cognitive impairment. This obser-
vation might be caused by the activating effect of Fe on
GSK3β [86], which neutralizes the effect of highly acti-
vated CDK5 on p-GSK3β suppression. Moreover, DFO
treatment highly induced the phosphorylation of GSK3β
(inactive form of GSK3β), which in turn downregulated
caspase-3 in the LPS-exposed mouse brain.
Since aberrant iron accumulation in the brain is found
in many diseases involving cognitive function decline
and neuroinflammation plays a pivotal role in many
iron-associated neurodegenerative diseases [20,31], we
measured the iron content and main proteins involved
in the maintenance of brain iron homeostasis in mice to
investigate the influence of LPS and DFO on iron me-
tabolism in the hippocampus that is responsible for
learning and memory function in the brain. As demon-
strated in this study, intracerebroventricular LPS led to a
significant increase in iron content (by 66.16%) and
DFO dramatically blocked this increase. Accompanied
with iron content, Fn accumulation and FPN reduction
occurred in the hippocampus of mice in the LPS group,
indicating that LPS triggered iron accumulation and ex-
port malfunction, which could cause neuronal injury.
Peptide hepcidin plays an essential role in maintaining
normal iron homeostasis mainly by downregulating
FPN, and it can be upregulated by LPS in neuron via
the IL-6/STAT3 signaling pathway, as Qian et al. dem-
onstrated [87,88], which is in line with our data. Other-
wise, DFO as a high-affinity iron chelator to bind Fe3+,
removes iron from neurons, which is excreted via
biliary-fecal and/or urinary routes. In the present study,
DFO dramatically blocked iron content increase, re-
versed Fn accumulation and weakened FPN reduction.
This result suggests that there may be causal relation-
ships between LPS-induced neuroinflammation, iron ac-
cumulation, and memory deficits, and DFO breaks this
tie by diminishing iron in neurons.
Increased levels of brain iron have been proposed to
cause neuronal injury via oxidative stress [89,90]. Accord-
ingly, under pathological conditions, iron would catalyze
free radical reactions, known as Fenton or Haber-Weiss
reactions, causing damage to lipids, DNA, and proteins. In
the present study, high levels of iron were found in the
mouse hippocampus after intracerebroventricular admin-
istration of LPS, suggesting that increased brain iron could
be a source of the redox active metals. Indeed, we found
significant changes in oxidative stress markers in mice
after LPS microinjection. Specifically, MDA in the hippo-
campus reached about twice that of the control, and SOD
Zhang et al. Journal of Neuroinflammation  (2015) 12:20 Page 11 of 13activity was reduced. It is tempting to speculate that in-
creased brain iron content leads to the generation of
toxic free radicals and the occurrence of oxidative
stress, ultimately leading to neuronal injury and cogni-
tive impairment. However, further studies are needed to
test this hypothesis.
Collectively, intracerebroventricular microinjection of
LPS caused transient upregulation of cytokines (TNF-α
and IL-1β), activation of microglia (Iba1), oxidative stress
(SOD and MDA), cell death (caspase-3 and GSK3β),
and iron accumulation (iron content, Fn and FPN) dur-
ing the acute phase. Nevertheless, pretreatment with
DFO alleviated these lesions and thereby improved LPS-
induced cognitive impairment by inhibiting brain iron
accumulation. Taken together, we could come to a con-
clusion that LPS triggers a transient neurocognitive
decline in a mouse model that is associated with brain
iron accumulation and a series of inflammatory cascade
response, which may be caused by the activation of the
iron regulation system to some extent; DFO reduces hip-
pocampal inflammation and consequently the pathological
progression by blocking iron accumulation in neurons,
eventually improving memory performance. DFO may
represent a strategy for preventing neuroinflammation-
associated cognitive impairment although the exact mech-
anism needs to be further clarified to complete and valid-
ate this intriguing conclusion.
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